Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 ACR responses, DAS28 C-reactive protein, and EULAR28 responses at week 24

From: A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritis

   AMG 108
  Placebo
(n= 203)
50 mg
(n= 204)
125 mg
(n= 203)
250 mg
(n= 203)
ACR response, n (%)a     
   ACR20 59 (29.1) 63 (30.9) (P = 0.746) 73 (36.0) (P = 0.168) 82 (40.4) (P = 0.022)
   ACR50 17 (8.4) 24 (11.8) (P = 0.323) 28 (13.8) (P = 0.113) 41 (20.2) (P < 0.001)
   ACR70 8 (3.9) 4 (2.0) (P = 0.259) 5 (2.5) (P = 0.575) 12 (5.9) (P = 0.492)
DAS28 CRP, mean change from baselineb -0.60 -0.69 (P = 0.213) -0.92 (P < 0.001) -1.18 (P < 0.001)
EULAR28 response, n (%)c     
   Good 16 (8%) 20 (10%) 28 (13.9%) 39 (19.5%)
   Moderate 61 (30.7%) 59 (29.3%) 76 (37.8%) 76 (38%)
   No response 122 (61.3%) 122 (60.7%) 97 (48.3%) 85 (42.5%)
  1. ACR, American College of Rheumatology; CRP, C-reactive protein; DAS28, Disease Activity Score (28-joint count); EULAR28, European League Against Rheumatism (28-joint count). aNonresponder imputation: missing ACR responses were imputed as nonresponder. P values are nominal without multiplicity adjustment, using Fisher's exact test. bObserved cases. P values are comparisons with placebo, using two-sided Wilcoxon rank-sum test. cEULAR28 response is classified as good, moderate, and no response based on the DAS28 ESR at week 24 and the DAS28 ESR improvement from baseline at week 24 [31].